Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

114
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
114
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

123
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
123
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

113
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
113
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

91
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
91

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rising prevalence of venous thromboembolism in gastrointestinal cancers: a nationwide analysis of 205 million hospitalizations, 2016-2022.

Journal of gastrointestinal oncology·2026
Same author

HSR26-239: Outcomes in Multiple Myeloma Hospitalizations With CAR-T Therapies in the United States.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

HSR26-239: Outcomes in Multiple Myeloma Hospitalizations With CAR-T Therapies in the United States.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Reply to Walter <i>et al.</i>: The Importance of "Yes, and…": Communication Skills Training for Pulmonary and Critical Care Medicine Fellows.

ATS scholar·2025
Same author

Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.

Journal of the American Heart Association·2024
Same author

Multiple Goals Theory and Communication Quality Analysis for Fellows Communication Training.

ATS scholar·2024

Related Experiment Video

Updated: Nov 18, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K

Anticoagulation in COVID-19: a single-center retrospective study.

Sohaib Sanan Roomi1, Maryum Saddique2, Waqas Ullah1

  • 1Jefferson Health-Abington, Abington, PA, USA.

Journal of Community Hospital Internal Medicine Perspectives
|February 8, 2021
PubMed
Summary

Therapeutic anticoagulation in COVID-19 patients significantly reduced in-hospital mortality, intensive care unit (ICU) upgrades, and mechanical ventilation needs. This approach is recommended over prophylactic anticoagulation for COVID-19 unless further trials indicate otherwise.

Keywords:
COVID-19anticoagulationthrombosis

More Related Videos

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
09:12

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

3.9K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

969

Related Experiment Videos

Last Updated: Nov 18, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K
Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
09:12

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

3.9K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

969

Area of Science:

  • Internal Medicine
  • Cardiology
  • Critical Care Medicine

Background:

  • COVID-19 is associated with a pro-thrombotic state, leading to microvascular thrombi.
  • The role of therapeutic anticoagulation in managing COVID-19 remains debated with limited evidence.

Purpose of the Study:

  • To investigate the impact of therapeutic anticoagulation on clinical outcomes in hospitalized COVID-19 patients.
  • To determine if therapeutic anticoagulation reduces in-hospital mortality, ICU transfer, mechanical ventilation, and acute renal failure.

Main Methods:

  • A retrospective cohort study involving 176 hospitalized COVID-19 patients.
  • Patients were divided into therapeutic and prophylactic anticoagulation groups.
  • Statistical analyses included independent t-tests and multivariate logistic regression to calculate odds ratios (aOR) and 95% confidence intervals (CI).

Main Results:

  • Therapeutic anticoagulation was associated with significantly lower adjusted odds ratios for in-hospital mortality (aOR 3.05), ICU upgrade (aOR 3.08), and mechanical ventilation (aOR 4.27).
  • No significant difference was observed in the rate of acute renal failure requiring dialysis between the groups (aOR 1.87).
  • Baseline characteristics and comorbidities were similar between the two groups.

Conclusions:

  • Therapeutic anticoagulation significantly reduces in-hospital mortality, ICU admission, and mechanical ventilation in COVID-19 patients.
  • This suggests therapeutic anticoagulation may be preferable to prophylactic anticoagulation for COVID-19 patients.
  • Further randomized controlled trials are needed to confirm these findings.